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Abstract
Infectious keratitis tops the list of diseases leading to visual impairment and 
corneal blindness. Corneal opacities, predominantly caused by infectious keratitis, 
are the fourth leading cause of blindness globally. In the developed countries, 
infectious keratitis is usually associated with contact lens wear, but in developing 
countries, it is commonly caused by trauma during agricultural work. The common 
causative organisms are bacteria, fungus, Acanthamoeba, and virus. Severe cases 
can progress rapidly and cause visual impairment or blindness that requires corneal 
transplantation, evisceration, or enucleation. The precise clinical diagnosis, accu-
rate diagnostic tools, and timely appropriate management are important to reduce 
the morbidity associated with infectious keratitis. Despite the advancement of diag-
nostic tools and antimicrobial drugs, outcomes remain poor secondary to corneal 
melting, scarring, or perforation. Eye care strategies should focus on corneal ulcer 
prevention. This review addresses the epidemiology, diagnostic approach, clinical 
manifestations, risk factors, investigations, treatments, and the update of major 
clinical trials about common pathogens of infectious keratitis.
Keywords: infectious keratitis, corneal ulcer, corneal scar, blindness,  
visual impairment
1. Introduction
Infectious keratitis tops the list of diseases leading to visual impairment and 
corneal blindness. Globally, it is approximated that 1.3 billion people live with visual 
impairment [1]. The major causes of corneal blindness included infectious keratitis, 
ocular trauma, trachoma, bullous keratopathy, corneal degenerations, and vitamin 
A deficiency [2]. Corneal opacities, predominantly caused by infectious keratitis, 
are the fourth leading cause of blindness globally [3]. Recent paper reported that 
3.5% of global blindness could be attributed to corneal opacity [4]. According to 
the goal of the “Vision 2020: The Right to Sight,” which was proposed by WHO, the 
prevention of avoidable corneal blindness should receive more awareness [5, 6].
Interestingly, the majority of visual impairment is avoidable [1]. Infectious kera-
titis accounts for 10% of avoidable visual impairment in the world’s least-developed 
countries [3]. The number of people with avoidable visual loss has increased con-
siderably because of population growth and aging. This trend will continue beyond 
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2020 [7] and will inevitably impact the eye care need in the near future. In the 
developed countries, infectious keratitis is usually associated with contact lens wear, 
but in developing countries, it is commonly caused by trauma during agricultural 
work [8–17]. Infectious keratitis is characterized by a corneal epithelial defect with 
underlying stromal inflammation caused by replicating microorganisms [14]. Acute 
eye pain and redness are the common presentation [14]. The common causative 
organisms are bacteria, fungus, Acanthamoeba, and virus [10, 17]. However, corneal 
infection involving more than one microorganisms such as bacteria and fungus is 
relatively uncommon [17] Microbial keratitis requires acute ophthalmic care and 
aggressive treatment to stop the disease progression and limit the extent of corneal 
scarring, which can cause loss of vision [14]. The precise clinical diagnosis, accurate 
diagnostic tools, and timely appropriate management are important to reduce the 
morbidity associated with infectious keratitis. This review addresses the epidemiol-
ogy, diagnostic approach, clinical manifestations, risk factors, investigations, treat-
ments, and the update of major clinical trials about common pathogens of infectious 
keratitis. The purpose of this review is to provide a concise and essential knowledge 
about common etiologic pathogens of infectious keratitis to improve understanding 
and reduce morbidity and visual loss due to this condition.
2. Global epidemiology, global etiologies, and burden of diseases
2.1 Global epidemiology
The precise prevalence of infectious keratitis is unknown [18]. The actual 
prevalence may be higher due to the underreporting or reporting under the term 
of corneal blindness, which also includes traumatic, infectious, inflammatory, 
and inherited causes [8]. Overall cases may exceed 2 millions cases per year world-
wide [8]. The global incidence of infectious keratitis shows wide disparity among 
regions. The incidence of infectious keratitis was high in south, south-east, and 
east Asia, but lower in developed world [8]. The estimated general incidence of 
infectious keratitis per 100,000 population per year varies from 11 to 27.6 in the 
United States [19, 20], 40.3–52.1 in the United Kingdom [8, 21], 6.3 in Hong Kong 
[22], 113 in India [23], 339 in Bhutan [24], 710 in Burma [24], and 799 in Nepal 
[25]. In contact lens wearers, the incidence is about 6 times higher [8, 18, 20]. It has 
been reported that nearly 90% of the global cases of ocular trauma and infectious 
keratitis leading to corneal blindness occur in developing countries [2].
2.2 Global etiologies
The principal organisms of infectious keratitis have regional variation [18]. 
In developed countries such as Europe [21, 26, 27], North America [28, 29], and 
Australia [14], the highest proportions of infectious keratitis are attributable to bac-
teria. This incidence correlated with the prevalence of contact lens wear and high 
gross national income [30]. On the contrary, in developing countries, the propor-
tions of infectious keratitis attributable to bacteria were less [31–33] than or similar 
to those from fungus [34]. The Asia Cornea Society Infectious Keratitis Study 
(ACSIKS) group that included data from 13 study centers and 30 subcenters from 
6626 eyes of 6563 subjects demonstrated the similar percentage of bacterial and 
fungal infections. Overall, bacterial keratitis was diagnosed in 2521 eyes (38.0%) 
and fungal keratitis in 2166 eyes (32.7%) [34]. But in India and China, fungal 
keratitis was the majority of nonviral microbial keratitis [34]. Similarly, data from 
the large trial in India by Lalitha et al. that included 17,948 patients demonstrated 
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that 6218 of 10,207 (60.9%) culture-positive patients had a fungal etiology [31]. The 
recent studies from China by Lin et al. [35] and Xie et al. [33] reported proportions 
of fungal keratitis to be 44.6% and 77.9%, respectively. Vision 2020: “The Right to 
Sight” also suggests that we acquire a clearer and more precise understanding of 
infectious keratitis in each country [6, 33].
The frequency of causative organisms of keratitis among different geography 
may vary by countries [30]. In North America, Australia, the Netherlands, and 
Singapore, the highest proportion of infectious keratitis was bacterial in origin. The 
highest proportion of pseudomonas keratitis was reported in a study from Bangkok, 
whereas the highest proportion of staphylococcal ulcers was reported in a study 
from Paraguay. On the other hand, the highest proportions of fungal keratitis were 
reported in studies from India and Nepal [30]. Interestingly, recent data from the 
Asia Cornea Society Infectious Keratitis Study (ACSIKS) group demonstrated that 
the commonest etiology of infectious keratitis was viral keratitis, which accounted 
for 47.7% [34]. A recent population-based study in China estimated that the 
prevalence of herpes simplex keratitis was 0.11%, similar to that in the United States 
and France [5].
For the worldwide frequency of Acanthamoeba keratitis, around 1% of infec-
tious keratitis was reported [30]. Although the number of infections caused by 
these organisms is low, Acanthamoeba keratitis is an emerging disease mostly due to 
the increased use of contact lens worldwide [36]. Cariello et al. reported the higher 
rate of 7.4% of infectious keratitis caused by Acanthamoeba in Brazil [37].
2.3 Burden of diseases
Despite the fact that infectious keratitis is a significant cause of corneal blind-
ness [2, 38, 39], there has been relatively little evidences available about the definite 
global burden of infectious keratitis. Moreover, the actual burden may be higher 
due to the underreport [8] and a fact that most of the patients reside in countries 
with less-developed economics [38].
Collier et al. reported the burden of this disease in the United States. Infectious 
keratitis causes an estimated 930,000 doctor’s office and outpatient clinic visits and 
58,000 emergency department visits per year. Nearly 80% of keratitis visits lead to 
antimicrobial prescriptions. The direct health care costs for keratitis and contact 
lens disorders were approximately 175 US dollars. Moreover, it consumed over 
250,000 hours of clinician time annually [8, 40].
Data from the national surveys in China and India reported that infectious kera-
titis is responsible for the major burden of corneal blindness [5, 23, 41]. However, in 
other endemic areas of infectious keratitis such as China and India, the actual costs 
were not available. It may be underreported or underestimated in poor rural and 
agricultural farm-based populations [8]. The cost of infectious keratitis is magni-
fied as it usually affects the poorest populations during their most productive years 
[8, 42]. Moreover, the cost may be derived from poor access to health care, corti-
costeroid abuse, inadequate empiric antibiotics, and difficulty to obtain diagnostic 
cultures that leads to delay presentation of or fulminant infection [8, 42].
3. Diagnostic approach
It is helpful for ophthalmologists to be familiar with the typical signs and symp-
toms of different organisms that are responsible for infectious keratitis. The provi-
sional diagnosis may help to ensure the prompt management prior to the revelation 
of the definite diagnosis from investigations.
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3.1 History
The common symptoms of infectious keratitis include pain, foreign body sen-
sation, redness of conjunctiva and eyelids, tearing, discharge, photophobia, blurry 
vision, eyelids swelling, and notice of a white mark on the cornea [24, 43, 44]. In 
Acanthamoeba keratitis, the patients usually have severe pain out of proportion to 
the corneal lesion because of perineuritis. Bacterial keratitis usually has an acute 
onset, and gradual onset of symptoms usually suggests nonbacterial causes such as 
atypical keratitis or fungal keratitis [43]. Careful history taking about risk factors 
of infectious keratitis will help confirm the diagnosis. The important risk factors 
such as history of eye trauma, contact lens wear and hygiene, history of ocular sur-
face disease, previous bacterial or HSV keratitis, history of corticosteroid abuse, 
hot tub exposure, prior ocular surgery, systemic diseases such as diabetes, immu-
nodeficiency, and vitamin A deficiency will aid in the clinical diagnosis [43–45].
3.2 Physical examination
If the ophthalmologist is familiar with the characteristics of different etiologic 
agents of infectious keratitis, this helps confirm the diagnosis and determine 
the possible etiologic organisms. A thorough physical examination from general 
appearance and eye examination will aid in the provisional clinical diagnosis 
[43–45]. Visual acuity will be invariably affected depending on the location of the 
lesion and degree of intraocular inflammation [43]. Intraocular pressure should be 
examined unless corneal perforation is suspected such as deep lesion on slit lamp 
examination, and visible protrusion of intraocular content unless corneal perfora-
tion is suspected [43]. Ocular hypotony will be present in perforation cases. On the 
other hand, a high intraocular pressure can be suggestive of HSV, which is associ-
ated with trabeculitis [43]. External examination for the general appearance, lid 
closure, blinking, and corneal sensation are vital to determine the predisposing fac-
tors. For example, the patient that has a lagophthalmos is usually prone to an infec-
tious keratitis at inferior cornea. A slit lamp examination is also crucial to determine 
the etiology of a suspected lesion. Eyelids may appear swollen, and conjunctiva 
may reveal injection and tearing and/or mucopurulent discharge. Ciliary flush is 
common. Cornea examination should document the characteristics of the lesion 
such as the size, shape, border, density, location, depth, and color. For instances, 
Pseudomonas ulcer usually shows the classic clinical feature of “ground glass 
appearance,” which is a diffuse ulceration with stromal infiltrate or edema involving 
adjacent or whole cornea [24]. The classical clinical picture of the filamentous fun-
gal keratitis is dry, raised infiltrate with feathery edges. A brown or dark pigmenta-
tion may be presented in dematiaceous fungal keratitis and can be an important 
diagnostic clue [24, 46]. The size and border of the lesion should be documented 
because it can suggest a positive response to a treatment if the size is decreased and/
or the border is consolidated [44]. The depth of the lesion should be evaluated. In 
fungal keratitis, if the lesion is superficial, it may have a better response to the anti-
fungal eye drop treatment than the deeper lesion because of poor ocular penetration 
and unpredictable bioavailability of antifungal agents [47]. If there is a significant 
corneal thinning and/or descemetocele, urgent management is required. The 
patient may have decreased visual acuity if the infiltration is located over the pupil 
or have a significant intraocular inflammation [24]. Fluorescein staining and cobalt 
blue light aid in the document of epithelial defect and detect the corneal perforation 
by Seidel test [24, 44]. The anterior chamber should be documented for a cell, flare, 
and/or hypopyon. Essential history and physical examination are listed in Table 1.
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3.3 Microbiological investigations
Most of the bacterial keratitis cases resolve with the empiric topical antibiotics 
before the results of culture are available [26, 44].
The smears and cultures are indicated as follows [44, 48]:
1. A corneal infiltrate is central, large, and/or is associated with significant stro-
mal involvement or melting.
2. The keratitis is chronic or unresponsive to broad-spectrum antibiotic  
therapy.
3. History of corneal surgeries is found.
4. Atypical clinical features that are suggestive of fungal, amoebic, or mycobacte-
rial keratitis are identified.
5. There are multiple locations of cornea infiltrates.
Corneal culture helps to identify the causative organisms and determine 
antibiotics sensitivity [44]. Moreover, culture can help in modifying therapy in 
Essential history Essential physical examination
• Duration of symptoms
• Eye trauma
• Contact lens wear (types and hygiene)
• Swimming, using a hot tub, or showering while 
wearing contact lenses
• Past ocular diseases
 ○ Previous infection, e.g., bacteria, fungus, herpes 
simplex virus (HSV)
• Past ocular surgery
• Previous and current eye drops usage
 ○ Current treatment
 ○ Contaminated ocular medication
 ○ Topical nonsteroidal anti-inflammatory drugs 
(NSAIDs)
 ○ Topical anesthetics
 ○ Topical corticosteroids
 ○ Preservatives
 ○ Glaucoma medications
• Past medical history
 ○ Medical conditions
 ○ Immunosuppression
• Medication allergies
• Visual acuity
• Intraocular pressure (contraindicated in 
corneal perforation)
• External examination
 ○ General appearance, lid closure, blinking, 
corneal sensation
• Slit lamp examination
 ○ Eyelid margins
 ○ Eye lashes abnormality
 ○ Discharge
 ○ Conjunctival injection, ciliary flush
 ○ Characteristics of lesion, size, shape, 
border, density, location, depth, color
 ○ Endothelial plaque
 ○ Seidel test
 ○ Pupillary examination
 ○ Anterior chamber reaction
 ○ Sclera
 ○ Foreign body
• Complete eye examinations
• Contralateral eye for clues to etiology
• Signs of previous corneal or refractive surgery
References based on references [43, 44].
Table 1. 
Essential history and examination in infectious keratitis patient.
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unresponsive cases and eliminating unnecessary medications to decrease ocular 
surface toxicity [44]. Corneal scraping should be obtained from the advancing 
borders of infected cornea. The hypopyon in bacterial keratitis cases is usually 
sterile, and aqueous and vitreous tapping should not be done unless suspected 
of microbial endophthalmitis. Cultures should be performed before starting 
antimicrobial therapy, and if cultures are negative, the ophthalmologist may 
consider stopping antibiotic treatment for 12 to 24 hours and then re-culturing 
the infectious keratitis [44]. The stain provides provisional diagnosis of patho-
genic organisms of infectious keratitis. However, cultures were the gold standard 
to identify the definitive pathogens and provided antibiotics susceptibility testing 
[26, 49]. Data from the large trial that enrolled 3300 eyes with infective keratitis 
in India demonstrated that the sensitivity of KOH was higher in the detection of 
fungi than that of Gram-stained smears (99.3%; 95% CI 98.6 to 99.6) and (89.2% 
(95% CI 87.3 to 90.8), respectively [50]. The Gram stain has diagnostic accuracy 
of 60–75% for bacteria keratitis detection and 35–90% for fungal keratitis [51]. 
The KOH alone has 62–99% sensitivity and 73–99% specificity for fungal kerati-
tis detection [51]. Giemsa stain has 40–85% sensitivity and 70–96% specificity in 
detecting fungal keratitis [51].
All media are examined for growth daily and are incubated for 1–2 weeks 
before considering negative culture. Bacteria such as atypical mycobacteria, 
Nocardia spp., and Acanthamoeba grow slowly and require prolonged incuba-
tion [52]. Nonnutrient agar plate should be observed for at least 10 days [49]. 
Fungus grows within 24 hours to maximum of 2 weeks, so prolonged incubation 
at least for two to 3 weeks before the culture is considered negative [49]. The 
vital stains and cultures that are used for infectious keratitis are  
concluded in Table 2.
Even among the cornea specialists, they can correctly differentiate bacte-
rial keratitis from fungal keratitis in less than 70% of cases [55]. Classic clini-
cal figures may be obscured in large keratitis due to tissue destruction [53]. 
Acanthamoeba keratitis may be responsible for many cases of clinically presumed 
herpes simplex keratitis [54]. Cultures and smears are the gold standard to 
diagnose bacterial and fungal keratitis, but fungal cultures consume several days 
to weeks to obtain growth and can be falsely negative for deep infiltrates [56]. In 
these cases, other investigations such as in vivo confocal microscopy (IVCM) and 
PCR may have a role.
3.3.1 In vivo confocal microscopy (IVCM)
Bacteria and virus cannot be identified by IVCM but Acanthamoeba and 
fungal filaments are large enough and can be visualized [56]. Early detection of 
Acanthamoeba keratitis is associated with favorable outcome. Two most commonly 
used types of corneal IVCM include slit-scanning (ConfoScan; Nidek Technologies) 
and laser-scanning (Heidelberg Retina Tomograph with Rostock Corneal Module) 
[56]. In vivo confocal microscopy provides a rapid, noninvasive diagnostic tool and 
monitors treatment response, which has 85.7 to 88.3% sensitivity and 81.4 to 91.1% 
specificity for fungal keratitis detection and 88.2 to 88.3% sensitivity and 91.1 to 
98.2% specificity for Acanthamoeba keratitis diagnosis [53–55, 57]. However, the 
branching angle of Fusarium and Aspergillus spp. was not easily differentiated by 
IVCM, and culture remains essential to address fungal species [58]. Amoebas are 
visible as double-walled cysts or as brightly reflective ovoid structures [54, 59]. 
However, diagnostic performance of IVCM is highly dependent on the operator’s 
experience [60].
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3.3.2 PCR
Although not yet widely available, the advantages of PCR are rapid specific iden-
tification and requiring small clinical sample [51, 61, 62]. PCR is generally a required 
test for viral diagnosis and detection of organisms that are difficult to culture such 
as Microsporidia, Mycobacterium tuberculosis, fungi, and Acanthamoeba [52, 61, 
63, 64]. PCR can be used as adjunct to smear and culture especially in cases where 
routine diagnostic procedures failure [65]. When compared to standard culture 
technique, real-time PCR had 100% sensitivity and 96% specificity in the diagnosis 
of Acanthamoeba keratitis [63].
4. Etiological agents of infectious keratitis
The common causative organisms of infectious keratitis are bacteria, fungus, 
Acanthamoeba, and virus [5, 14, 18, 34]. This review addresses the epidemiology, clini-
cal manifestations, risk factors, and treatment of each pathogen. The classic clinical 
features of common causative organisms of infectious keratitis are show in Figure 1.
Type Organism visualized
Stains Gram stain Most of the pathogenic bacteria, fungi, 
Acanthamoeba
Giemsa stain Chlamydia trachomatis
Herpes simplex virus
Varicella zoster virus
Acanthamoeba
Potassium hydroxide (KOH) Fungi, Acanthamoeba
Calcofluor white Fungi, Acanthamoeba
Special stains
• Ziehl-Neelsen and/ or Kinyoun stain
• Immunoflorescence stain
• Periodic acid Schiff (PAS) stain
• Gomori methenamine silver (GMS) stain
• Mycobacterium and Nocardia
• Chlamydiae and viruses
• Fungi
• Fungi, Acanthamoeba
Cultures Blood agar Aerobic and facultatively anaerobic bacteria, 
fungi such as P. aeruginosa, S. aureus, S. 
epidermidis, and S. pneumoniae
Chocolate agar Aerobic and facultatively anaerobic bacteria 
including H. influenzae, N. gonorrhea
MacConkey agar Lactose fermenting (e.g., Escherichia 
coli, Enterobacter, Klebsiella) VS Lactose 
nonfermenting bacteria (Salmonella, Shigella, 
Proteus spp., Pseudomonas)
Thioglycolate broth Aerobic and facultatively anaerobic bacteria
Sabouraud dextrose agar Fungi
Optional culture media
• Lowenstein Jensen medium
• Nonnutrient agar
• Mycobacterium and Nocardia spp.
• Acanthamoeba
References based on [18, 24, 43, 48–54].
Table 2. 
Common stains and cultures used to identify common pathogens of infectious keratitis.
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4.1 Bacterial keratitis
4.1.1 Epidemiology
Bacterial pathogens are responsible for a majority of infectious keratitis cases 
especially in developed countries and in contact lens wearers [21, 26, 27, 30, 43]. The 
keratitis can occur after a break in the corneal epithelium that allows bacteria to enter 
[43, 45]. The important pathogens of bacterial keratitis can be classified as follows: [18].
1. Gram-positive bacteria
• Gram-positive cocci, e.g., Staphylococcus aureus, Coagulase-negative staphylo-
coccus, Streptococcus pneumoniae
• Gram-positive bacilli, e.g., Nontuberculous mycobacteria (Mycobacterium 
fortuitum, Mycobacterium chelonae), Nocardia spp.
2. Gram-negative bacteria
• Gram-negative bacilli; e.g., Pseudomonas aeruginosa, Enterobacteriaceae, 
Moraxella, Haemophilus
• Gram-negative cocci; e.g., Neisseria gonorrhea
The major bacterial causes are Staphylococcus aureus, Coagulase-negative 
staphylococcus, Streptococcus pneumoniae Pseudomonas aeruginosa, and Streptococcus 
spp. [18, 24, 66, 67].
4.1.2 Manifestations
The patient with bacterial keratitis usually presents with rapid onset of pain, 
photophobia, blurry vision, and eye redness. Slit lamp examination usually reveals 
Figure 1. 
The classic clinical features of common causative organisms of infectious keratitis: (a) Bacterial keratitis. 
(b) Fungal keratitis. (c) Herpes necrotizing stromal keratitis. (d) Early Acanthamoeba keratitis. (e) Late 
Acanthamoeba keratitis.
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clearly defined infiltrations with stromal edema and inflammation (Figure 1)  
[43, 45]. The classic clinical figures for Gram-positive cocci are “localized round or 
oval ulceration, grayish-white stromal infiltrates, distinct borders with minimal 
surrounding stromal haze, or no edema” [18, 24]. Nontuberculous mycobacteria 
usually have a “cracked wind-shield”-type of appearance. Nocardia spp. usually 
has a multiple small white infiltrate that resembles “wreath pattern.” Gram nega-
tive bacterial infection usually presented as a dense stromal suppuration, hazy 
surrounding cornea, “immune ring” [18]. Pseudomonas keratitis may develop 
as ring abscess without epithelial defect [24]. Gram-negative bacterial keratitis 
can perforate within few days if not properly managed [24]. Keratitis caused 
by Gram-negative cocci usually present with lid edema and copious purulent 
discharge, perforate rapidly, and may have bilateral involvement [24]. However, 
the slit-lamp manifestation alone may not specify the definite pathogens. For 
instance, satellite lesions, immune ring, and endothelial plaques may be present 
in both bacterial and fungal keratitis and cannot help to differentiate between 
bacterial and fungal keratitis [24]. Appropriate microbiological investigation is 
needed to confirm the specific pathogens. Even among the cornea specialists, they 
can correctly differentiate culture-proven bacterial keratitis and smear-positive 
fungal keratitis in photographs in less than 70% of cases [55]. In the case that the 
keratitis is unresponsive to the initial treatment or has an atypical course, the 
mixed-organism infection such as bacterial combined with fungal keratitis should 
be suspected [17].
4.1.3 Risk factors
The keratitis usually occurs after a break in the corneal epithelium [45, 68]. 
The major risk factors are contact lens wear, corneal abrasions, and ocular trauma 
[43, 45]. Other important risk factors include prior ocular surgery, chronic ocular 
disease, use of corticosteroids, contaminated ocular medications, and diabetes 
[66]. Contact lens wear and lagophthalmos were identified as the major risk fac-
tors for the development of Gram-negative infection [18, 66]. Preexisting ocular 
disease and previous HSV keratitis were associated with Gram-positive infectious 
keratitis [18, 68].
4.1.4 Treatment
Topical antibiotic eye drops can achieve high tissue concentration and are 
the preferred method of treatment in most cases [69]. Topical fluoroquinolones 
usually prescribed as first-line empiric initial treatment of suspected bacte-
rial keratitis are at least as effective as combined fortified antibiotics [69]. 
Even though the susceptibility of Gram-negative bacteria to fluoroquinolone 
monotherapy was high, the susceptibility of Gram-positive bacteria was less 
and more variable [11, 68]. Because of shift in antibiotics resistance patterns, 
in some regions, fluoroquinolone monotherapy is not recommended for severe 
infectious keratitis, but combined fortified antibiotics should be prescribed 
instead [11]. Fortified topical antibiotics should be considered for large and/
or visually significant keratitis, unresponsive to initial treatment, especially 
if a hypopyon is present [11, 44]. In contact lens wearers, the disease pattern 
and etiologic organisms may be altered to increase incidence of Pseudomonas 
aeruginosa [70]. Fluoroquinolones and aminoglycosides are good empirical 
antibiotics for infectious keratitis treatment [70]. In noncontact lens wearers, it 
tends to be caused by other organisms such as coagulase-negative Staphylococci, 
Staphylococcus aureus, and Streptococcus pneumoniae, which are largely sensitive 
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to fluoroquinolones [70]. In terms of patients’ tolerance to medications, fluo-
roquinolones are more favorable than combined fortified antibiotics [69]. The 
initial empirical therapy should be prescribed until definite microbial identity 
and sensitivity are disclosed [11]. For central or severe keratitis, a loading dose 
every 5–15 minutes followed by frequent applications such as every hour is 
recommended [24, 44]. Subconjunctival antibiotics may be useful in impending 
scleral spreading and questionable adherence to topical treatment. In cases of 
scleral or intraocular extension of infection, perforation, or systemic infection, 
systemic therapy may be helpful [24, 44]. Oral tetracycline class antibiotics 
(including doxycycline) could be used to inhibit corneal stromal thinning by 
matrix metalloproteinases [71].
Reevaluation depends on the extent and severity of disease. The initial treat-
ment should be modified when the eye shows a lack of improvement or stabiliza-
tion within 48 hours [44]. Coexisting conditions and/or complications, such as 
glaucoma, corneal perforation, endophthalmitis, and eye lid abnormalities, should 
be treated promptly. The progressive corneal stromal thinning should be managed 
by application of tissue adhesive, penetrating keratoplasty, or lamellar keratoplasty 
[44]. Therapeutic keratoplasty may be indicated in cases of large corneal perfora-
tion or uncontrolled infection [24, 44]. Corneal transplantation in active infection 
has high failure rate [34]. However, the result is usually better than fungal keratitis, 
and 40–50% of these patients recover useful vision [24].
4.2 Fungal keratitis
4.2.1 Epidemiology
Fungal keratitis, potentially blinding condition, is an important cause of 
infectious keratitis [72]. Fungal keratitis is very common, accounts for 30–62% 
of infectious keratitis, in tropical region, but is uncommon in temperate climates 
[72]. The important pathogens of fungal keratitis can be classified as follows  
[18, 24, 45, 61, 72]:
Filamentous fungi such as Aspergillus spp., Fusarium spp., Curvularia spp., and 
Scedosporium spp. are frequent causes.
Yeasts such as Candida albicans, Candida spp., and Cryptococcus spp., are less 
common [18]. The fungi invade the ocular surface only when it is compromised 
or has a defect in the epithelial barrier and access into the corneal stroma [72]. 
However, the keratitis may present as chronic infiltration or even with an intact 
epithelium [56].
4.2.2 Manifestations
Symptoms of fungal keratitis typically are not as acute as other microbial 
keratitis [72]. The pain, redness, and lid edema are similar with bacterial keratitis. 
Early fungal keratitis may appear like a dendritic ulcer of herpes simplex virus. The 
feathery edge is a pathognomonic clinical feature [24]. Satellite lesions, immune 
ring, and unlevelled hypopyon may support the diagnosis but not specific clinical 
figures [24]. The surface is raised with grayish-white creamy infiltrates, which may 
or may not appear dry [24]. The keratitis due to pigmented fungi such as Curvularia 
spp., Bipolaris, and Exserohilum spp. will appear as brown or dark, raised, dry, 
rough, leathery plaque on the corneal surface [24, 46]. A recent report from the 
Mycotic Ulcer Treatment Trial II (MUTT II) stated that the presence of hypopyon at 
baseline indicated 2.28 times the odds of the patient developing corneal perforation 
and/or needing therapeutic keratoplasty [73].
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4.2.3 Risk factors
Fungal keratitis must be suspected if the patient is in agricultural work [24]. For 
filamentous fungi, trauma with subsequent exposure to plant or vegetable material is 
usually the only predisposing factor, although previous use of corticosteroids, native 
medicine, and contact lens wear are increasing in importance as risk factors [24, 45, 61]. 
For yeast, there is usually some systemic or ocular surface compromise [61].
4.2.4 Treatment
The currently available antifungal drugs have multiple drawbacks such as poor 
ocular penetration, unpredictable bioavailability, and adverse effects associated with 
systemic medications [47]. Filamentous fungal keratitis is difficult to treat despite the 
use of topical and systemic antifungal agents and adjuvant surgery, such as corneal 
transplantation [61]. About one-third of fungal keratitis patients have pharmacologi-
cal failure that required surgical interventions to get rid of infection [72]. Thus, early 
diagnosis of fungal keratitis is the most important determinant of their prognosis 
[56]. Topical corticosteroids are contraindicated in the treatment of fungal keratitis 
and also in the early postoperative therapeutic keratoplasty [72]. For filamentous 
fungi, the first-line drug is 5% natamycin, and the second-line drugs are 1% itracon-
azole and 2% Econazole [18]. There is evidence that natamycin is more effective than 
voriconazole in the treatment of filamentous fungal keratitis especially in Fusarium 
keratitis [74, 75]. Candida keratitis is usually initially treated with 0.15% amphotericin 
B followed by fluconazole eye drop if the first-line drug is not responsive [18]. The 
systemic antifungal agents, including oral ketoconazole, itraconazole, voriconazole, 
and posaconazole, are needed for severe keratitis or cases with extension beyond the 
anterior chamber [18, 43]. Seventy percent of Fusarium keratitis with deep lesion does 
not respond to sole medical treatment, and surgical intervention may be required 
[61]. More than 80% of Aspergillus keratitis responds to medical therapy alone; 
however, in deep keratitis, surgical intervention is needed [61]. For Candida keratitis, 
medical therapy generally has a favorable response, and the presence of deep lesions 
is not a major issue [61]. Severe fungal keratitis patients that are still smear-positive 
despite being pretreated with appropriate antifungal agents may benefit from aggres-
sive multimodality therapy [76]. Various drugs and route of antifungal agents for 
fungal keratitis are available as listed below [9, 18, 47, 60, 61, 75, 77–79].
1. Topical: natamycin (5%), amphotericin B (0.15–0.3%), Econazole (1%), Flucy-
tosine (1%), clotrimazole (1%), miconazole (1%), ketoconazole (1–2%), itra-
conazole (1%), fluconazole (1%), voriconazole (1–2%), and caspofungin (0.5%)
2. Subconjunctiva: fluconazole (0.5–1.0 mL of a 2% solution), miconazole 
(10 mg in 0.5 mL), and voriconazole (10 mg)
3. Intravenous: amphotericin B and miconazole (600–1200 mg/day), and vori-
conazole (6 mg/kg)
4. Oral: ketoconazole (200–600 mg/day), itraconazole (100–200 mg/day), fluco-
nazole (50–200 mg/day), and voriconazole (400 mg/day)
5. Intrastromal injection: voriconazole (50 μg per 0.1 mL) and amphotericin B 
(5–10 μg per 0.1 mL)
6. Intracameral: voriconazole (50 μg /0.1 mL) and amphotericin B (5–10 μg/0.1 mL)
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Surgical debridement of the epithelium and base of the fungal keratitis is 
crucial in the management because it debulks the organisms and enhances drug 
penetration into cornea [79]. Surgery for fungal keratitis, ranging from lamellar or 
penetrating keratoplasty to evisceration or enucleation, plays a role as an adjunct to 
medical therapy for initial management and when medical therapy fails or impend-
ing corneal perforation [51, 61, 79]. The prognosis of fungal keratitis is worse than 
bacterial keratitis [80]. The course is favorable with medical treatment in 50—70% 
of cases. A surgery is required in 30 to 54% of cases [80]. These infections may 
lead to loss of the globe in 10 to 25% of cases [80]. High risk of developing corneal 
perforation and the need to undergo therapeutic penetrating keratoplasty (TPK) 
are due to infiltrate size of more than 6.6 mm, an infiltrate involving the posterior 
one-third of the stroma, and the presence of a hypopyon [73]. Unfortunately, 
recurrence keratitis can occur approximately 6–7% after therapeutic keratoplasty 
[81]. Hypopyon, corneal perforation, and corneal infection expanding to limbus 
and lens infection are predominant risk factors for the recurrence of fungal keratitis 
after corneal transplantation [81]. After therapeutic keratoplasty, systemic and 
topical antifungal treatments should be used for 2 weeks routinely and possibly for 
6 to 8 weeks in high-risk cases [81]. Generally, if no typical signs of recurrence were 
present 2 weeks after surgery, low-concentration topical steroids may be adminis-
tered with caution [81].
4.3 Viral keratitis
4.3.1 Epidemiology
Herpes simplex virus (HSV) is a common cause of viral keratitis and the most 
common cause of unilateral infectious corneal blindness in the world [5, 9]. Varicella-
zoster and cytomegalovirus can also cause viral keratitis but are much less common 
[9]. The prevalence of viral keratitis was 0.11% in a recent population-based study 
[5]. The majority of corneal HSV-1 infection is not the outcome of primary ocular 
infection, but in response to reactivation of latent virus from the trigeminal ganglion 
[82]. However, recurrent corneal epithelial infection with HSV-1 can have stromal 
involvement known as herpes stromal keratitis (HSK), which can be necrotizing, 
nonnecrotizing, or a mix of both [82, 83]. One study with HSV stromal keratitis 
reported that disease was of the necrotizing type in 7%, nonnecrotizing in 88%, and 
a mix of the two in 5% [84]. In this review, we address only the herpes necrotizing 
stromal keratitis that may mimic infectious keratitis from other organisms.
4.3.2 Manifestations
Viral keratitis differs from bacterial and fungal keratitis in that it can become 
recurrent and chronic [9]. In necrotizing HSV stromal keratitis, necrosis, ulcer-
ation, and dense leukocytic infiltration of the stroma are present and often associ-
ated with an overlying epithelial defect and neovascularization [18, 83, 85]. The 
viral keratitis diagnosis is usually based on clinical findings [43] and diagnosis 
by exclusion. However, in atypical cases, the investigations such as tissue culture, 
ELISA, and PCR may aid in the diagnostic confirmation [43].
4.3.3 Risk factors
The risk of HSV reactivation can occur after excimer laser refractive surgery such as 
LASIK or PRK. The exposure to ultraviolet light during corneal collagen cross-linking 
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(CXL) can reactivate latent HSV infection [86]. Previous stromal keratitis increased 
the risk of stromal keratitis, and the risk was strongly related to the number of  
previous episodes [86, 87].
4.3.4 Treatment
Both immune and active viral replications are responsible for the disease patho-
genesis [83]. In contrast to nonnecrotizing stromal keratitis where topical cortico-
steroid is the mainstay treatment, oral acyclovir is used to control the viral invasion 
and replication in cornea, while low-dose topical corticosteroids are given to control 
inflammation in necrotizing stromal keratitis [18]. Topical CsA administration can 
resolve stromal inflammation and neovascularization in 50 and 64% of cases, respec-
tively [83]. Without timely and effective treatment, necrotizing HSV stromal keratitis 
can rapidly lead to corneal perforation [83]. Amniotic membrane transplantation onto 
the ocular surface promotes corneal epithelial healing and reduces stromal inflamma-
tion, angiogenesis, and scarring [83]. Various oral antiviral agents to treat active viral 
replication and prevent recurrences are available as mentioned below [86]:
1. Acyclovir: 800 mg, 3–5 times/day, 7–10 days
2. Valacyclovir: 1 g, 3 times per day, 7–10 days
3. Famciclovir: 500 mg, 2 times/day, 7–10 days
Data from the Herpetic Eye Disease (HEDS) study concluded that the HSV 
stromal keratitis patients who received 400 mg oral acyclovir twice per day for 
12 months had reduced rate of recurrent HSV stromal keratitis by about 50%. The 
research about HSV vaccination is underway, and no vaccine is currently available 
[83, 86, 88].
4.4 Acanthamoeba keratitis
4.4.1 Epidemiology
Acanthamoeba is a free-living protozoan found in soil and in freshwater that can 
cause keratitis primarily in contact lens (CLs) wearers [45]. The epidemiological 
features of Acanthamoeba keratitis may vary among different geographic regions, 
climate, and living environments [36].
Acanthamoeba is responsible for less than 5% of infectious keratitis [24].
4.4.2 Manifestations
The classic presentation of patients with Acanthamoeba keratitis is pain out 
of proportion to ophthalmological finding, photophobia, and slow progressive 
course [36, 43, 45]. The keratitis usually presents in one eye, but in CL users, it 
can present with bilateral involvement [36]. The examination may reveal various 
findings depending on the stage of ocular involvement. Within the first month, 
the disease can manifest as diffuse punctate epithelial lesions, dendritic-like 
lesions (mimic herpes simplex epithelial keratitis), epithelial or subepithelial 
infiltrates, or perineural infiltrates, and ring-shaped stromal infiltrates may be 
presented [45, 89]. After a month, the disease is characterized by ring-shaped 
stromal infiltrates, anterior uveitis, endothelial plaque, and disciform keratitis 
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[36]. Limbitis is a common feature in both early and advance disease [36]. If not 
managed properly, the disease can progress and late stage findings can develop 
such as scleritis, iris atrophy, anterior synechiae, secondary glaucoma, mature 
cataract, chorioretinitis, and retinal vasculitis [89].
4.4.3 Risk factors
The majority of cases are found in contact lens wearers [43]. Infections related to 
contact lens are often associated with improper wear such as poor cleaning, overuse, 
and sleeping or swimming with them [36]. Other risk factors for Acanthamoeba 
keratitis are cornea trauma or exposure to contaminated fresh water, soil, or vegeta-
tion and after corneal laser refractive surgery [36, 43, 90].
4.4.4 Treatment
There are two principal issues that lead to severe visual outcomes that are mis-
diagnosis or late diagnosis, and lack of a fully effective therapy for highly resistant 
cyst stage of Acanthamoeba [36]. The current diagnostic techniques are insensitive 
and poor turn around time. Moreover, the better yields and rapid test such as PCR 
or IVCM are not widely available [62]. This keratitis should be treated as soon as 
possible to prevent loss of visual acuity or even blindness [36]. Thus, ophthalmolo-
gists should be familiar with varied clinical pictures of Acanthamoeba keratitis. 
Currently, there are n0 FDA-approved medications for Acanthamoeba keratitis [62]. 
Treatment for Acanthamoeba keratitis includes the following medications [62]:
1. Diamidines (propamidine and hexamidine)
2. Biguanides (polyhexamethylene biguanide and chlorhexidine)
3. Aminoglycosides (neomycin and paromomycin)
4. Imidazole/triazoles (voriconazole, miconazole, clotrimazole, ketoconazole, 
and itraconazole)
Unfortunately, only the biguanides have been proven to be effective against 
both the cysts and trophozoite forms of Acanthamoeba [43]. The combination 
therapy may be of benefit [89]. The earlier the diagnosis, the better the chances 
of having a good visual prognosis [43]. In the early stage, epithelial debridement 
and 3 to 4 months of anti-amoebic therapy are enough [45]. Confocal microscopy 
is the most suitable tool to monitor the keratitis during the course of treatment 
[62]. However, after a prolonged and maximal medical treatment, recurrence can 
occur. Topical corticosteroids may mask clinical signs of Acanthamoeba keratitis, 
encystment, and an increase in number of trophozoites [89]. However, a patient 
with Acanthamoeba keratitis and severe inflammation may also benefit from this 
drug [89]. Optical keratoplasty may be considered after 3 to 6 months disease-free 
interval to avoid the late recurrence [62].
5. Complications of infectious keratitis
Despite timely and appropriate topical antibiotic treatment, surgical interven-
tions such as tectonic or therapeutic keratoplasty may be required to preserve the eye 
and vision [91]. However, performing keratoplasty in a “hot eye” is associated with 
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an increased risk of recurrence of the disease and graft rejection/failure [91]. The 
visual outcomes of infectious keratitis may be poor from various complications such 
as corneal scarring or perforation, irregular astigmatism, development of glaucoma, 
cataracts, endophthalmitis, and vision loss [92]. Moreover, the advanced infectious 
keratitis that required therapeutic keratoplasty had decreased quality of life. The 
characteristics associated with corneal perforation in infectious keratitis were the 
lack of corneal vascularization, delay in starting initial treatment, and failure to start 
fortified antibiotics [42, 93]. Inappropriate use of traditional medicines or topical 
steroids abuse and delay in referral to an ophthalmologist for diagnosis and treat-
ment are all responsible for unnecessary visual loss [24]. The primary care provider 
should be aware about complication of infectious keratitis. The standardized referral 
and treatment guideline for patients with infectious keratitis on their first contact at 
primary care level is needed [93].
6. Prevention of infectious keratitis
Due to the magnitude of the problem, limited access to treatment, inadequate 
well-trained medical personnel, costs of treatments, and the often poor visual 
outcomes, prevention may be one of the feasible public health strategies avail-
able [5, 34]. Avoiding or correcting predisposing factors may reduce the risk of 
keratitis [44]. Patients with risk factors for keratitis should be educated about their 
risk, made familiar with the signs and symptoms of keratitis, and informed that 
they have to consult an ophthalmologist promptly if they encounter such warning 
signs or symptoms to minimize permanent visual loss [44, 94]. In the developed 
countries, infectious keratitis is usually associated with contact lens wear, but in 
developing countries, it is commonly caused by trauma during agricultural work 
[8–10, 13]. Interestingly, data from the recent trial reported that “Up to 50% of 
contact lens wearer are not compliant with hand washing procedures” [95]. Poor 
hand hygiene is a risk factor of developing infectious keratitis in contact lens wear-
ers [95]. Developing effective prevention strategy that is circulated to contact lens 
users is crucial to reduce the incidence of infectious keratitis [40]. Although the use 
of protective eyewear in industrial and agricultural work can prevent ocular injury, 
the actual utilization of such protective eyewear has been found to be consistently 
low, even in industrialized countries with robust workplace safety regulations [34]. 
The protective eyewear during these works should be compelled. The outcome of 
corneal injury with secondary infection can be improved by early diagnosis and 
prompt treatment with appropriate antibiotics at the primary level of eye care [24]. 
Because most cases of infectious keratitis are the result of corneal trauma, the use of 
0.5–1% chloramphenicol eye ointment three times per day for 3 successive days for 
superficial corneal trauma in primary care is recommended by WHO to prevent the 
development of infectious keratitis [24].
7. Update of major clinical trials about common pathogens
7.1 Steroids for Corneal Ulcers Trial (SCUT)
The large, randomized, placebo-controlled, double-masked multicenter clinical 
trial that compared 12 months clinical outcomes in patients receiving adjunctive 
topical 1.0% prednisolone sodium phosphate or topical placebo in the treatment of 
bacterial keratitis found that adjunctive topical corticosteroid therapy may improve 
best spectacle-corrected visual acuity (BSCVA) in bacterial corneal keratitis 
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not caused by Nocardia species. But no significant difference was identified by 
treatment for scar size for non-Nocardia ulcers. However, scar size was larger in 
Nocardia keratitis [96, 97].
7.2 Mycotic Ulcer Treatment Trial (MUTT) I
The double-masked, multicenter trial that compare topical 5% natamycin vs. 
1% voriconazole in the treatment of filamentous fungal keratitis showed a benefit 
of topical natamycin over topical voriconazole for filamentous fungal keratitis, 
particularly among those caused by Fusarium. Natamycin-treated cases had signifi-
cantly better 3-month BSCVA, less likely to have perforation or require therapeutic 
penetrating keratoplasty than voriconazole-treated cases [74].
7.3 Mycotic Ulcer Treatment Trial (MUTT) II
The randomized, placebo-controlled, double-masked multicenter clinical trial 
showed that adding oral voriconazole to topical antifungal agents in the treatment 
of severe filamentous fungal keratitis did not improve the rate of corneal perfora-
tion, the need for therapeutic penetrating keratoplasty (TPK), microbiologic cure at 
6 days, rate of re-epithelialization, BSCVA, and infiltrate and/or scar size. However, 
oral voriconazole did increase in nonserious adverse events and cost [98].
7.4 The Herpetic Eye Disease Study (HEDS) I
The Herpetic Eye Disease Study (HEDS) was a series of randomized, double-
masked, placebo-controlled clinical trials that studied ocular HSV and is still the 
gold standard for ocular HSV management [86]. HEDS showed a significant benefit 
of topical corticosteroids and oral acyclovir for HSV stromal keratitis [84, 99].
7.5 The Herpetic Eye Disease Study (HEDS) II
HEDS II showed that oral acyclovir decreased the recurrence rate of any type of 
HSV keratitis by 50% approximately [88, 100].
8. Recent treatments of infectious keratitis
The mainstay treatment of infectious keratitis is antimicrobial drugs, which 
is fraught with drug resistance [11]. However, despite appropriate diagnosis and 
urgent treatment, medical treatment failure may occur and lead to corneal perfora-
tion [101] and/or therapeutic keratoplasty. Novel treatment is emerging to expand 
the armamentarium of tools to manage infectious keratitis and improve treatment 
outcomes [101]. The interesting managements in recent years are Photo-Activated 
Chromophore for Keratitis–Corneal Cross-Linking (PACK-CXL) and photody-
namic antimicrobial therapy (PDAT) [91, 101–103].
8.1 PACK-CXL
The mechanism of action of PACK-CXL is antimicrobial activity of UV light, 
which can directly damage the DNA and RNA of various etiologic organisms [91]. 
Moreover, synergistic effect is derived from reactive oxygen species released from 
photoactivated riboflavin, which can directly damage DNA and cell membranes 
of microorganisms [91]. These effects can increase corneal resistance to enzymatic 
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degradation and increase corneal rigidity. So, it may decrease corneal melting and 
avoid emergency therapeutic keratoplasty [102, 104]. As microbial resistance to 
microbicidal therapy increases, CXL might be effective in treating advanced infec-
tious keratitis as an adjuvant and also for treating early-stage bacterial infiltrates as 
first-line treatment [102, 104]. However, CXL is not routinely used for infectious 
keratitis because of the uncertainty of its safety and efficacy. A recent systematic 
review and meta-analysis from Ting et al. demonstrated that adjuvant PACK-CXL 
could expedite the resolution of bacterial keratitis and potentially fungal keratitis, 
in terms of size of infiltrates [105, 106]. However, adjuvant PACK-CXL did not 
shorten the time to corneal healing [107]. Unfortunately, in Acanthamoeba, viral, 
fungal, and mixed keratitis, treatment outcome was insufficient [91, 103]. However, 
when rose Bengal was used instead of riboflavin, PACK-CXL was effective against 
Acanthamoeba [108]. UV radiation in PACK-CXL may exacerbate viral keratitis [109].
8.2 Photodynamic antimicrobial therapy (PDAT)
Since CXL was found to be ineffective against fungal keratitis, potential blind-
ing disease, PDT was proposed as an alternative measure [103]. Photodynamic 
therapy (PDT) involves the activation of a photosensitizing agent that reacts with 
oxygen to create reactive oxygen species (ROS). The light using in PDT ranges from 
ultraviolet-A (UV-A) to near-infrared wavelengths. These ROS react with intracel-
lular components and produce cell inactivation and death [110]. In vitro study 
demonstrated that Rose Bengal-mediated PDT successfully inhibited the growth 
of Fusarium solani, Aspergillus fumigatus, and Candida albicans [103]. Moreover, 
the Rose Bengal- and riboflavin-mediated PDT demonstrated in vitro inhibition 
of methicillin-resistant Staphylococcus aureus (MRSA) [111]. Riboflavin PDAT 
strengthens the corneal collagen fibers, delays keratolysis, and prevents a corneal 
perforation in humans [112]. This can be used as an adjunct treatment in bacterial 
and fungal keratitis with good long-term outcome [112].
9. Conclusion
Infectious keratitis tops the list of the diseases leading to visual impairment and 
corneal blindness. The precise clinical diagnosis, accurate diagnostic tools, and 
timely appropriate management are important to reduce the morbidity associated 
with infectious keratitis. Although most patients improve after medical and surgi-
cal management, their vision may be considerably decreased [15]. A few emerging 
treatments used to manage infectious keratitis show good preliminary outcomes for 
selected cases of infectious keratitis, although additional research is required before 
it is accepted as mainstream treatment for this potentially blinding condition. 
Therefore, the importance of eye protection [18], hygiene education, and contact 
lens care and hygiene must be strongly emphasized.
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